Central Government Prohibits Nimesulide Formulations for Animal Use

According to an official notification, the Central Government has determined that Nimesulide formulations are likely to involve risks to animals and that safer alternatives are readily available. After consulting the Drugs Technical Advisory Board, the government has concluded that it is necessary and expedient to impose this ban in the public interest.

Massive Drug Raid in Kolkata Uncovers Rs. 6.60 Crore Worth of Spurious Medicines

The raid targeted a wholesale premises located in Kolkata, and led to the seizure of a substantial quantity of suspected spurious drugs, including anti-cancer and anti-diabetic medications. Additionally, investigators discovered empty packing materials at the site, further raising concerns about the authenticity of the products.

CDSCO Publishes Not Of Standard Quality And Spurious Alert For November 2024

The NSQ drug list specifies a total of 70 drugs that were detected to be deficient by State Lab Drugs Control Laboratories. The NSQ drug list for central CDSCO laboratories specifies a total of 41 drugs that were detected to be deficient. Additionally, CDSCO has also identified 2 drugs to be spurious.

NPPA Approves Separate Pricing for Cipla’s Synchrobreathe Inhaler Device

The National Pharmaceutical Pricing Authority (NPPA) has approved separate pricing for Cipla Ltd.’s “Synchrobreathe Inhaler Device” when used with specific Budesonide and Formoterol formulations. This decision follows recommendations from a Multidisciplinary Committee of Experts and aims to promote incremental innovation in drug delivery.

NPPA Fixes Retail Prices For 65 Formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 65 pharmaceutical formulations. The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.

NPPA Revises Ceiling Prices for Scheduled Formulations

The National Pharmaceutical Pricing Authority (NPPA) has issued an order fixing ceiling prices for several essential medicines and revising prices for others based on a review order. The new prices, effective from December 19, 2024, aim to ensure affordability and accessibility of essential drugs.

India’s Pharmaceutical Industry With Ambitious Growth Plans

India’s pharmaceutical industry is a significant force in the global market, boasting a strong domestic presence and a rapidly growing export sector. National Institutes of Pharmaceutical Education & Research (NIPERs) spearhead research efforts.

Government Ramps Up Production of Pharmaceuticals and Medical Devices in India

The PLI scheme for Bulk Drugs, with a financial outlay of Rs. 6,940 crore, incentivizes the manufacturing of essential Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs). With a budget of Rs. 15,000 crore, the PLI Scheme for Pharmaceuticals focuses on high-value products like patented/off-patented drugs, biopharmaceuticals, complex generics, and anti-cancer drugs. The PLI Scheme for Promoting Domestic Manufacturing of Medical Devices targets high-end medical devices previously imported into India.

CDSCO Publishes Not Of Standard Quality And Spurious Alert For October 2024

The NSQ drug list specifies a total of 34 drugs that were detected to be deficient by State Lab Drugs Control Laboratories. The NSQ drug list for central CDSCO laboratories specifies a total of 56 drugs that were detected to be deficient. Additionally, CDSCO has also identified 3 drugs to be spurious.